| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Adenylyl cyclase; cAMP and cGMP phosphodiesterases; store-operated Ca2+ channels.
|
|---|---|
| ln Vitro |
MDL-12330A inhibits adenylyl cyclase activity in rat liver plasma membrane preparations at concentrations ranging from 10 µM to 5 mM. It potentiates insulin secretion via blockade of voltage-dependent K+ channels in pancreatic beta cells. The compound inhibits cAMP and cGMP phosphodiesterases, which may mask its effect on adenylyl cyclase.
|
| ln Vivo |
MDL-12330A has been used to block cyclic AMP signaling in mesenchymal stem/stromal cells (MSC). It has also been used as an adenylyl cyclase blocker to test its effect on locomotor activity based on tail suspension test (TST) in mice. The compound blocks vasopressin-induced short-circuit current (SCC).
|
| Enzyme Assay |
In vitro enzyme assays measure adenylyl cyclase activity by quantifying cAMP production from ATP in membrane preparations. MDL-12330A is incubated with rat liver plasma membranes, ATP, and varying compound concentrations (typically 1 µM to 5 mM). The reaction is terminated by boiling, and cAMP is measured by radioimmunoassay or competitive ELISA. IC50 values are calculated from dose-response curves. Phosphodiesterase inhibition is assessed using [3H]cAMP or [3H]cGMP as substrates.
|
| Cell Assay |
Cellular assays are performed using pancreatic beta cells or mesenchymal stem cells. Cells are pre-incubated with MDL-12330A (1-100 µM) for 30-60 minutes. cAMP levels are measured by ELISA following stimulation with forskolin or vasopressin. Insulin secretion is measured by radioimmunoassay. Calcium imaging using fluorescent dyes (e.g., Fura-2) assesses the compound's effect on store-operated Ca2+ entry. Cell viability is monitored using MTT assays to confirm non-cytotoxic concentrations.
|
| Animal Protocol |
In vivo studies use mouse models such as the tail suspension test (TST). MDL-12330A is administered intraperitoneally at doses ranging from 1-20 mg/kg. Locomotor activity is assessed using automated activity chambers. For pancreatic studies, mice receive compound injections and blood glucose and insulin levels are measured. Tissues are collected for cAMP measurements and signaling pathway analysis.
|
| ADME/Pharmacokinetics |
MDL-12330A hydrochloride has a molecular weight of 377.01 g/mol and formula C23H36N2·HCl. Purity is ≥98% by HPLC. Store at +4°C. Soluble in DMSO and water. For in vivo use, formulate in saline or suitable vehicle. The compound is stable as a powder for up to 2 years when stored desiccated.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is publicly available for MDL-12330A. As a research compound, it is not intended for human use and has not undergone formal toxicological evaluation. Standard preclinical safety assessments would include hERG channel inhibition for cardiac safety, CYP450 enzyme inhibition for drug-drug interaction potential, and cytotoxicity profiling in relevant cell lines. The compound is supplied for laboratory research use only.
|
| References | |
| Additional Infomation |
MDL-12330A is a research-grade chemical probe for studying adenylyl cyclase and cyclic nucleotide signaling. It is not approved for clinical use. Also known as RMI 12330A. The compound is a hydrochloride salt with CAS number 40297-09-4. It should be stored at +4°C and protected from light. References include Guellaen et al. (1977) and Hunt and Evans (1980).
|
| Molecular Formula |
C23H37CLN2
|
|---|---|
| Molecular Weight |
377.01
|
| Exact Mass |
376.265
|
| CAS # |
40297-09-4
|
| PubChem CID |
6917816
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
515ºC at 760 mmHg
|
| Melting Point |
148 - 152 °C
|
| Flash Point |
265.2ºC
|
| LogP |
6.853
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
26
|
| Complexity |
384
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C1CCCCCC(=NCCCCC1)N[C@H]2CCC[C@H]2C3=CC=CC=C3.Cl
|
| InChi Key |
CKOPQUCSDBVAQG-VROPFNGYSA-N
|
| InChi Code |
InChI=1S/C23H36N2.ClH/c1-2-4-6-11-18-23(24-19-12-7-5-3-1)25-22-17-13-16-21(22)20-14-9-8-10-15-20;/h8-10,14-15,21-22H,1-7,11-13,16-19H2,(H,24,25);1H/t21-,22-;/m0./s1
|
| Chemical Name |
N-[(1S,2S)-2-phenylcyclopentyl]-1-azacyclotridecen-2-amine;hydrochloride
|
| Synonyms |
MDL12330A; MDL 12330A; MDL-12330A
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6524 mL | 13.2622 mL | 26.5245 mL | |
| 5 mM | 0.5305 mL | 2.6524 mL | 5.3049 mL | |
| 10 mM | 0.2652 mL | 1.3262 mL | 2.6524 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
